Table 2 Collagen as a prognostic factor for cancer patients

COLI

Intactness

Colorectal cancer

Changes dynamically at stages I to IV, peaking at stage II

[249]

Intactness

Prostate cancer

Metastasis

[250]

COL1A1

Breast cancer

Development and progression along with COL3A1 and COL4A1

[251]

COL1A2

Colorectal cancer

Proliferation, migration, and invasion

[252]

COL1A2

Hepatocellular cancer

Metastasis

[253]

N-terminal telopeptide

NSCLC

Overall survival

[254]

N-terminal telopeptide

Head and neck SCC

Overall survival along with N-terminal telopeptide of COLIII

[255]

Pyridinoline crosslinked C-terminal telopeptide (serum)

Breast cancer

Recurrence

[256]

N-terminal telopeptide (urine)

Breast cancer with bone metastases

Survival prognosis with zoledronic acid treatment for 3 months

[257]

COLII

COL2A1

High-grade serous ovarian cancer

Recurrence

[258]

COL2A1

Chondrosarcoma

Frequent mutations

[259]

COLIII

COL3A1

Breast cancer

Irregular margin status and mitotic activity

[260]

COLIV

Intactness

Advanced gastric carcinoma

The depth of wall penetration and stage

[261]

Intactness

Oral SCC

Positive lymph node status

[262]

Intactness

Colorectal cancer

Liver metastases

[263]

7S domain (serum)

Hepatocellular carcinoma

Intractable ascites

[264]

COL4A1

PDAC

Aggressive progression

[265]

COL4A1 (urine)

Bladder cancer

Recurrence

[266]

COL4A3

Gastric carcinomas

Cancer size, lymphatic invasion, venous invasion, TNM stage, and histologically distinction

[267]

COLV

Intactness

Resected NSCLC

Overall survival

[268].

COLVI

COL6A1

Cervical cancer

Overall and recurrent-free survival

[269]

COLXI

COL11A1

Esophageal SCC

Advanced clinical stage and lymph node metastases

[270]

COLXIII

COL13A1 (urine)

Bladder cancer

Recurrence

[266]

COLXVII

Intactness

Colorectal cancer

Invasion and metastasis

[271]

Intactness

SCC

Invasion

[272]

Intactness

Colon cancer

Metastasis

[273]

COLXXIII

Intactness (tissue and urine)

NSCLC

Recurrence

[274]